Company’s subsidiaries for the 3rd quarter ending 30 September 2018 which has already been examined by the Company’s auditor. The results can be summarized as follows; The Company’s consolidated financial

) Public Company Limited (“the Company”) has submitted the consolidated audited the third quarter and 9-month period of the year 2024 financial statements ended November 30, 2024 which were audited by

. DOD017/2562 May 8, 2019 Re: Management’s Discussion and Analysis (MD&A) of the Consolidated Financial Results for Quarter 1 of 2019 To: The President The Stock Exchange of Thailand DOD Biotech Public

November 13, 2006 February 28, 2020 Subjects : Report of Operating Performance for the Year 2019 Attention : President of the Stock Exchange of Thailand The Consolidated net profit of Eastern

Quarter Ended 31 March, 2020 Page 1 Executive Summary Unit : Million baht 2020 2019 Total revenues * 4,506.78 4,014.33 492.45 12.3 Total cost and expenses * 2,522.92 2,311.10 211.82 9.2 Gain (Loss) on

make further decision. 2. Operating Results (Company and Subsidiaries) Total revenue of the consolidated financial statements for Q3/2019 amounted 72.6 million baht compared to Q3/2018 with total revenue

Consolidated Financial Results for The Year 2019 For the year ended December 31st, 2019 Consolidated Profit & Loss of Global Consumer Public Company Limited Unit: Million Baht Y 2019 Y 2018 Change %YoY Revenues

Q2/2018 ∆% Q1/2019 ∆% Revenues from sales and services 484,581 469,770 3% 489,694 -1% Interest income 2,381 129 1,746% 2,184 9% Gain on disposal of assets - - 2,119 -100% Other income 7,251 3,503 107

Thailand CH. Karnchang Public Company Limited (“the Company”) and its subsidiaries would like to clarify the consolidated operating result and financial position for the three-month ended March 31, 2018 as

Comparison is as follows: THB’000 Q2/2018 Q2/2017 ∆% Q1/2018 ∆% Revenues from sales and services 469,770 502,981 -7% 529,514 -11% Interest income 129 485 -73% 121 7% Gain on disposal of assets - - 309,034 -100